Patents by Inventor Eric Chojnicki

Eric Chojnicki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods including a recombinant human MAB that promotes CNS remyelination
    Patent number: 8968735
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: March 3, 2015
    Assignees: Mayo Foundation for Medical Education & Research, Acorda Therapeutics, Inc.
    Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
  • Compositions and Methods including a Recombinant Human MAB that Promotes CNS Remyelination
    Publication number: 20130309240
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Application
    Filed: March 7, 2013
    Publication date: November 21, 2013
    Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
  • Compositions and methods including a recombinant human MAB that promotes CNS remyelination
    Patent number: 8460665
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Grant
    Filed: May 17, 2004
    Date of Patent: June 11, 2013
    Assignees: Mayo Foundation for Medical Education and Research, Acorda Therapeutics, Inc.
    Inventors: Elliot A. Gruskin, Eric Chojnicki, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez
  • Compositions and methods including a recombinant human mab that promotes cns remyelination
    Publication number: 20070086999
    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like.
    Type: Application
    Filed: May 17, 2004
    Publication date: April 19, 2007
    Inventors: Elliot Gruskin, Eric Chojnicki, Arthur Warrington, Allan Bieber, Moses Rodriguez
  • Methods for regulating weight and size of animals
    Publication number: 20060093650
    Abstract: The invention provides methods and compositions for regulating weight and size in animals.
    Type: Application
    Filed: November 2, 2005
    Publication date: May 4, 2006
    Inventors: Jeffrey Hillman, Eric Chojnicki, Ravi Orugunty